Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing
Journal of Clinical Lipidology · 2026-07 · 20 (7) · 1490-1497
DOI: 10.1016/j.jacl.2026.05.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-07. Verfasst von Benjamin M Helm und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical & Molecular Genetics, Indiana University School of Medicine, (Helm and Clary) Indianapolis, IN, United States; Indiana Universi…. Hauptthemen laut MEDLINE: Lipoprotein(a), Hyperlipoproteinemia Type II, Genetic Testing. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] and familial hypercholesterolemia (FH) are common, underdiagnosed monogenic dyslipidemias that significantly increase cardiovascular risk. OBJECTIVE: We investigated whether standard clinical risk factors-low-density lipoprotein cholesterol (LDL-C), family history, and personal history of premature atherosclerotic cardiovascular disease (pASCVD)-can accurately distinguish these conditions. METHODS: We analyzed 378 lipid clinic patients receiving Lp(a) screening and FH genetic testing with multinomial logistic regression. RESULTS: we found that while higher LDL-C and younger age were associated with FH, personal/family histories of pASCVD failed to differentiate between FH, elevated Lp(a), or dual diagnoses. Genetic testing for FH and Lp(a) measurement revealed that 22.5% had FH, 35.7% had elevated Lp(a), and 12.7% had both. Despite statistical associations, predicted probabilities for each diagnosis overlapped considerably, and clinical risk factors commonly used in FH clinical diagnostic criteria would insufficiently distinguish these genetic disorders. CONCLUSIONS: Results demonstrate that clinical risk factors and scoring systems cannot reliably substitute diagnostic FH genetic testing and Lp(a) measurement-essential for accurate diagnosis and management for these high-risk disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, (Helm and Clary) Indianapolis, IN, United States; Indiana University Health, (Helm and Huerta) Indianapolis, IN, United States. Electron…
- Indiana University Health, (Helm and Huerta) Indianapolis, IN, United States.
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, (Helm and Clary) Indianapolis, IN, United States; Department of Medicine, Division of Cardiology, Indiana University School of Medicine,…
Zitieren
APA
Helm, B. M., Huerta, V., & Clary, J. M. (2026). Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing. Journal of Clinical Lipidology, 20(7), 1490-1497. https://doi.org/10.1016/j.jacl.2026.05.003
Vancouver
Helm BM, Huerta V, Clary JM. Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing. Journal of Clinical Lipidology. 2026;20(7):1490-1497. doi:10.1016/j.jacl.2026.05.003
BibTeX
@article{Helm2026,
author = {Helm, Benjamin M and Huerta, Victor and Clary, Julie M},
title = {Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {7},
pages = {1490--1497},
doi = {10.1016/j.jacl.2026.05.003}
}
EUVIMED